Статья

Necroptosis in Immuno-Oncology and Cancer Immunotherapy

J. Sprooten, P. De Wijngaert, I. Vanmeerbeek, S. Martin, P. Vangheluwe, S. Schlenner, D. Krysko, J. Parys, G. Bultynck, P. Vandenabeele, A. Garg,
2020

Immune-checkpoint blockers (ICBs) have revolutionized oncology and firmly established the subfield of immuno-oncology. Despite this renaissance, a subset of cancer patients remain unresponsive to ICBs due to widespread immuno-resistance. To "break" cancer cell-driven immuno-resistance, researchers have long floated the idea of therapeutically facilitating the immunogenicity of cancer cells by disrupting tumor-associated immuno-tolerance via conventional anticancer therapies. It is well appreciated that anticancer therapies causing immunogenic or inflammatory cell death are best positioned to productively activate anticancer immunity. A large proportion of studies have emphasized the importance of immunogenic apoptosis (i.e., immunogenic cell death or ICD); yet, it has also emerged that necroptosis, a programmed necrotic cell death pathway, can also be immunogenic. Emergence of a proficient immune profile for necroptosis has important implications for cancer because resistance to apoptosis is one of the major hallmarks of tumors. Putative immunogenic or inflammatory characteristics driven by necroptosis can be of great impact in immuno-oncology. However, as is typical for a highly complex and multi-factorial disease like cancer, a clear cause versus consensus relationship on the immunobiology of necroptosis in cancer cells has been tough to establish. In this review, we discuss the various aspects of necroptosis immunobiology with specific focus on immuno-oncology and cancer immunotherapy.

Цитирование

Похожие публикации

Версии

  • 1. Version of Record от 2020-08-01

Метаданные

Об авторах
  • J. Sprooten
    Department of Cellular and Molecular Medicine, Laboratory of Cell Stress & Immunity (CSI), KU Leuven, 3000 Leuven, Belgium;, jenny.sprooten@kuleuven.be, (J.S.);, pieter.dewijngaert@student.kuleuven.be, (P.D.W.);, isaure.vanmeerbeek@kuleuven.be, (I.V.)
  • P. De Wijngaert
    Department of Cellular and Molecular Medicine, Laboratory of Cell Stress & Immunity (CSI), KU Leuven, 3000 Leuven, Belgium;, jenny.sprooten@kuleuven.be, (J.S.);, pieter.dewijngaert@student.kuleuven.be, (P.D.W.);, isaure.vanmeerbeek@kuleuven.be, (I.V.)
  • I. Vanmeerbeek
    Department of Cellular and Molecular Medicine, Laboratory of Cell Stress & Immunity (CSI), KU Leuven, 3000 Leuven, Belgium;, jenny.sprooten@kuleuven.be, (J.S.);, pieter.dewijngaert@student.kuleuven.be, (P.D.W.);, isaure.vanmeerbeek@kuleuven.be, (I.V.)
  • S. Martin
    Department of Cellular and Molecular Medicine, Laboratory of Cellular Transport Systems, KU Leuven, 3000 Leuven, Belgium;, shaun.martin@kuleuven.be, (S.M.);, peter.vangheluwe@kuleuven.be, (P.V.)
  • P. Vangheluwe
    Department of Cellular and Molecular Medicine, Laboratory of Cellular Transport Systems, KU Leuven, 3000 Leuven, Belgium;, shaun.martin@kuleuven.be, (S.M.);, peter.vangheluwe@kuleuven.be, (P.V.)
  • S. Schlenner
    Department of Microbiology, Immunology and Transplantation, KU Leuven, 3000 Leuven, Belgium;, susan.schlenner@kuleuven.be
  • D. Krysko
    Department of Human Structure and Repair, Cell Death Investigation and Therapy Laboratory, Ghent University, 9000 Ghent, Belgium;, Dmitri.Krysko@ugent.be, Department of Pathophysiology, Sechenov First Moscow State Medical University (Sechenov University), Moscow 119146, Russia
  • J. Parys
    Department of Cellular and Molecular Medicine and Leuven Kanker Instituut (LKI), Laboratory of Molecular and Cellular Signaling, KU Leuven, 3000 Leuven, Belgium;, jan.parys@kuleuven.be, (J.B.P.);, geert.bultynck@kuleuven.be, (G.B.)
  • G. Bultynck
    Department of Cellular and Molecular Medicine and Leuven Kanker Instituut (LKI), Laboratory of Molecular and Cellular Signaling, KU Leuven, 3000 Leuven, Belgium;, jan.parys@kuleuven.be, (J.B.P.);, geert.bultynck@kuleuven.be, (G.B.)
  • P. Vandenabeele
    Department of Biomedical Molecular Biology, Ghent University, 9000 Ghent, Belgium;, Peter.Vandenabeele@irc.vib-Ugent.be, VIB Center for Inflammation Research, 9052 Ghent, Belgium, Methusalem Program, Ghent University, 9000 Ghent, Belgium
  • A. Garg
    Department of Cellular and Molecular Medicine, Laboratory of Cell Stress & Immunity (CSI), KU Leuven, 3000 Leuven, Belgium;, jenny.sprooten@kuleuven.be, (J.S.);, pieter.dewijngaert@student.kuleuven.be, (P.D.W.);, isaure.vanmeerbeek@kuleuven.be, (I.V.)
Название журнала
  • Cells
Том
  • 9
Выпуск
  • 8
Страницы
  • 1823
Издатель
  • MDPI
Тип документа
  • journal article
Тип лицензии Creative Commons
  • CC BY
Правовой статус документа
  • Свободная лицензия
Источник
  • dimensions